~~<i id='4F0A660604'><strike id='4F0A660604'><tt id='4F0A660604'><pre id='4F0A660604'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：entertainment 2025-10-02 14:15:01 - browse：2

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Antibody drugs appear effective. Now can we make enough of them?

focus

explore

entertainment

focus

leisure time

focus

AdobeEverymorning,VictoriaRasberrygetsupbefore6a.m.,walkstothebedroomdownthehall,andhelpsher8-year-o

WSS

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Readout Newsletter: Illumina, CRISPR, Regeneron

'Patient friction coefficient' can gauge a clinical trial's patient burden

Blinken talks high

hotspot

leisure time

focus

Trump demands the U.S. pay no more for drugs than other countries … again

This gene therapy has record $4.25 million price. It's saved children.

George Santos makes 1st court appearance after pleading not guilty to 13 counts

With Wegovy coverage, Medicare patients may face high costs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Companies helping big Covid

Virginia high school admissions case could be legal follow

How are insurers handling Leqembi and related scans?

Tori Bowie and the unacceptable rates of Black maternal death

Chinese researcher claims birth of first gene

explore

Adam's Take: Intra

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Antibody drugs appear effective. Now can we make enough of them?

Yancopoulos of Regeneron works to expand Dupixent success

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

entertainment

focus

leisure time

focus